- Claris collects $118M to take eye drop into pivotal testing next yearClaris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a blinding disease with no pharmaceutical treatment options. It's a ...Endpoints · 20m ago↗ source
- GSK to start three-year plan to save cash, takes £1.33B hit on cough trial failureGSK said Tuesday it is rolling out a three-year restructuring program designed to cut costs and streamline its focus on key advanced assets. The UK drugmaker said in its second-quarter earnings r…Endpoints · 44m ago↗ source
- Apnimed eyes up to $160M IPO to prep for sleep apnea drug launchIf the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.